PharmaVigilant enhances clinical trial management system
11 August 2010
PharmaVigilant has launched I-Vault 2.5, the enhanced version of its electronic Trial Master File (TMF) system. This new version offers easier access to the critical trial data that sponsors need to make important decisions related to their clinical trial quickly and effectively.
I-Vault 2.5 improves usability, administration and notification capabilities for seamless site startup, site closeout and IRB submissions, drastically reducing costly trial delays and roadblocks.
By offering unlimited rights and roles and enabling global scalability, PharmaVigilant's enhanced eTMF system offers improved accuracy and analysis of trial data. Flexibility is key, particularly for complex trials, and I-Vault 2.5 allows each sponsor to determine which trial documents they wish to collect and how they would like them organized. This level of customization makes it easier for sponsors to adhere to study startup and closeout timelines while saving time by making disparate data easier and faster for sponsors to find.
"Sponsors need to convert their trial master files yesterday, so the need for robust, full-function products that can scale globally are in demand in the market. PharmaVigilant is committed to aggressive investments in our technology, and as a result we are widening the gap between ours and our competitors' offerings," said James DeSanti, founder and CEO of PharmaVigilant.
"With this newest version of I-Vault 2.5, our clients can better isolate trial inefficiencies and achieve significantly higher quality and cost savings. PharmaVigilant continues to produce innovative and unique technologies that are changing the landscape of the clinical trial industry."